GlassScriptPhysician profile
Arati A Reddy
NPI 1306803028
$66,096.32
in general payments reported to CMS, 2019-2025
19 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $109 · 2021: $4,291 · 2022: $8,420 · 2023: $16K · 2024: $22K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Travel and Lodging: $5,076 · Food and Beverage: $4,236 · Consulting Fee: $2,588 · Education: $19.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $24,651.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,937.50 |
| Travel and Lodging | $5,076.30 |
| Food and Beverage | $4,236.06 |
| Consulting Fee | $2,587.50 |
| Education | $19.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $42,153.18 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $21,255.00 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Novo Nordisk INC | $413.83 | 2019-2020 | |
| Amgen INC. | $336.24 | 2019-2025 | Evenity, Prolia |
| Madrigal Pharmaceuticals | $288.89 | 2024-2025 | Rezdiffra |
| Corcept Therapeutics | $278.33 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $249.59 | 2021-2022 | |
| Beta Bionics, INC. | $209.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $190.23 | 2019-2025 | Omnipod, Omnipod |
| Tandem Diabetes Care, INC. | $183.03 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Antares Pharma, INC. | $127.53 | 2022 | |
| Shire North American Group INC | $117.47 | 2019 | |
| Sequel Med Tech, LLC | $78.68 | 2025 | Twiist |
| Boston Scientific Corporation | $69.16 | 2025 | Watchman Access System |
| Senseonics, Incorporated | $69.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $22.28 | 2024 | |
| Medtronic Minimed, INC. | $19.73 | 2019 | |
| Cequr Corporation | $18.75 | 2023 | Cequr Simplicity |
| Radius Health, INC. | $16.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arati Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.